A 42-year-old immunocompromised male (CD4 count 85 cells/μL) from a cave-dwelling region in Himachal Pradesh presents with a 4-week history of fever, weight loss, hepatosplenomegaly, and pancytopenia. Blood cultures and bone marrow aspirate smears show numerous small (2–4 μm), oval yeast cells within macrophages and monocytes. Fungal culture on Sabouraud dextrose agar at 37°C is pending. The patient is started on empirical antifungal therapy. Which of the following is the drug of choice for disseminated histoplasmosis in this severely immunocompromised patient?

Explanation

## Treatment of Disseminated Histoplasmosis in Severe Immunosuppression ### Clinical Context This patient has: - Severe immunosuppression (CD4 < 100 cells/μL) - Disseminated histoplasmosis (fever, hepatosplenomegaly, pancytopenia, fungemia) - Geographic exposure (cave dwellings, Himachal Pradesh) - Microbiological confirmation (2–4 μm intracellular yeast in blood and bone marrow) **Key Point:** Disseminated histoplasmosis in severely immunocompromised patients is a medical emergency with high mortality if untreated. Treatment requires aggressive induction therapy followed by prolonged maintenance. ### Treatment Algorithm ```mermaid flowchart TD A[Disseminated Histoplasmosis<br/>CD4 < 100]:::outcome --> B{Severity?}:::decision B -->|Severe/CNS involvement| C[Liposomal Amphotericin B<br/>3-5 mg/kg IV daily]:::action B -->|Moderate| D[Amphotericin B deoxycholate<br/>0.5-1 mg/kg IV daily]:::action C --> E[Continue 1-2 weeks<br/>until clinical improvement]:::action D --> E E --> F[Switch to Itraconazole<br/>200-400 mg PO daily]:::action F --> G[Maintenance therapy<br/>until CD4 > 150 x 2 months]:::action G --> H[Immune reconstitution<br/>with ART]:::outcome ``` ### Antifungal Regimens for Histoplasmosis | Clinical Scenario | Induction | Duration | Maintenance | Duration | | --- | --- | --- | --- | --- | | **Disseminated (severe)** | Liposomal Amphotericin B 3–5 mg/kg IV daily | 1–2 weeks | Itraconazole 200–400 mg PO daily | Until CD4 > 150 × 2 months | | **Disseminated (moderate)** | Amphotericin B deoxycholate 0.5–1 mg/kg IV daily | 1–2 weeks | Itraconazole 200–400 mg PO daily | Until CD4 > 150 × 2 months | | **Mild-moderate pulmonary** | Itraconazole 200 mg PO daily | 3 months | — | — | | **CNS involvement** | Liposomal Amphotericin B 3–5 mg/kg IV daily | 4–6 weeks | Itraconazole 200–400 mg PO daily | Until CD4 > 150 × 2 months | ### Why Liposomal Amphotericin B? **High-Yield:** Liposomal formulation is preferred over conventional amphotericin B deoxycholate because: 1. **Higher efficacy** — achieves better tissue penetration and fungicidal activity 2. **Lower nephrotoxicity** — critical in patients with baseline renal impairment 3. **Better CNS penetration** — important if dissemination includes meningitis 4. **Reduced infusion reactions** — better tolerated in prolonged therapy **Clinical Pearl:** In India, disseminated histoplasmosis in HIV/AIDS patients is an AIDS-defining illness. Early initiation of antiretroviral therapy (ART) alongside antifungal therapy is essential for immune reconstitution. ### Maintenance Therapy with Itraconazole **Key Point:** After clinical improvement with amphotericin B (1–2 weeks), switch to oral itraconazole 200–400 mg daily for maintenance. Continue until: - CD4 count recovers to > 150 cells/μL - AND sustained for ≥ 2 months on ART **Tip:** Itraconazole has excellent bioavailability and CNS penetration. Monitor drug levels if available (target 1–5 μg/mL). ### Why Not Fluconazole or Voriconazole Monotherapy? **Warning:** Azole monotherapy (fluconazole or voriconazole) is **inadequate** for induction therapy in disseminated histoplasmosis because: - Slower fungicidal activity compared to amphotericin B - Higher relapse rates in severe immunosuppression - Risk of treatment failure and death - Fluconazole has **poor CNS penetration** if meningitis develops **Mnemonic: "AMP-first, then AZOLE"** — Amphotericin B for induction in severe disease, then switch to azole (itraconazole) for maintenance once stable.